Sterilized heterocyclidene-acetamide-derivative-containing suspension

MYPI2025001924A0Undetermined Publication Date: 2024-03-29SENJU PHARMA CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001924
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-29
Filing Date
2023-09-28
Publication Date
2024-03-29

AI Technical Summary

Technical Problem

Current dry eye treatments, such as eye drops, often require frequent administration due to poor redispersibility of heterocyclidenacetamide derivatives, leading to inconsistent delivery and reduced patient adherence.

Method used

A heat-treated or gamma ray sterilized aqueous suspension of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide with a nonionic surfactant, which improves redispersibility by reducing the number of shakes or inversions required for uniform dispersion.

Benefits of technology

The improved redispersibility ensures stable and efficient administration of the active ingredient, enhancing pharmacological effect and patient convenience by allowing for easier and more consistent treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure provides a suspension ophthalmic solution having exceptional re-dispersibility. More specifically, the present disclosure provides an aqueous suspension containing heat-treated (E)-2-(7-trifluoromethylchroman-4-yldene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmacologically acceptable salt or solvate thereof. In particular, the present disclosure relates to technology for improving the re-dispersibility of a suspension that contains a heterocyclidene acetamide derivative or to formulation technology based thereupon.
Need to check novelty before this filing date? Find Prior Art

Description

Sterilized suspension containing heterocyclideneacetamide derivatives

[0001] The present disclosure relates to the fields of medicine, healthcare, biology, biotechnology, etc. In particular, the present disclosure relates to a technology for improving the redispersibility of a suspension containing a heterocyclideneacetamide derivative, and a formulation technology based thereon.

[0002] The number of dry eye patients in Japan is estimated to be at least 8 million, and the number is estimated to be approximately 22 million, including potential patients who use over-the-counter eye drops without visiting a doctor. It is estimated that there are over 1 billion dry eye patients worldwide. In modern society, the use of television, computers, mobile devices, and other devices increases the frequency of staring at screens, reducing the number of blinks. Furthermore, the use of air conditioners and other devices dries the air, resulting in increased tear evaporation and leading to dry eye. Furthermore, refractive surgery and the use of contact lenses can result in dry eye. Symptoms associated with dry eye include ocular discomfort, dryness, burning, and irritation of the ocular surface.

[0003] When dry eye occurs, the above symptoms appear as subjective symptoms, and treatment requires regular eye drops over a long period of time. Therefore, many of the currently commercially available dry eye treatments are of the frequent administration type. For example, Diquas (registered trademark) eye drops usually need to be instilled six times a day, Hyalein (registered trademark) eye drops usually need to be instilled five to six times a day, and Mucosta (registered trademark) eye drops usually need to be instilled four times a day.

[0004] A composition containing (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, or use thereof for treating dry eye has been disclosed (Patent Document 1).

[0005] Patent Document 1: International Publication No. 2021 / 066144 Pamphlet

[0006] The present disclosure provides an aqueous suspension having excellent redispersibility, which contains heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, which is a heterocyclideneacetamide derivative, or a pharmaceutically acceptable salt or solvate thereof.

[0007] Accordingly, the present disclosure provides the following: (Item 1) An aqueous suspension comprising heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof. (Item 1-1) The aqueous suspension according to the above items, wherein the heat treatment is dry heat treatment. (Item 2) The aqueous suspension according to the above items, wherein the heat treatment is a treatment within a sterilization process. (Item 2-1) The aqueous suspension according to the above items, wherein the treatment within the sterilization process is dry heat sterilization. (Item 3) The aqueous suspension according to any one of the above items, further comprising a nonionic surfactant. (Item 4) The aqueous suspension according to any one of the above items, wherein the heat treatment comprises heat treatment at a temperature lower than about 180°C. (Item 5) The aqueous suspension according to any one of the preceding items, wherein the heat treatment comprises heat treatment at about 100 to about 175°C. (Item 6) The aqueous suspension according to any one of the preceding items, wherein the heat treatment comprises heat treatment at about 100 to about 170°C. (Item 7) The aqueous suspension according to any one of the preceding items, wherein the heat treatment comprises heat treatment at about 150 to about 170°C. (Item 8) The aqueous suspension according to any one of the preceding items, wherein the heat treatment is carried out for about 30 minutes to about 5 hours. (Item 9) The aqueous suspension according to any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is about 0.0001 w / v% to about 1 w / v%. (Item 10) The aqueous suspension according to any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is about 0.001 w / v% to about 0.5 w / v%. (Item 11) The aqueous suspension according to any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is about 0.01 w / v % to about 0.05 w / v %. (Item 12) The aqueous suspension according to any one of the preceding items, wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil. (Item 13) The aqueous suspension according to any one of the preceding items, wherein the nonionic surfactant is tyloxapol.(Item 14) The aqueous suspension according to any one of the preceding items, wherein the concentration of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, in the aqueous suspension is about 0.01 w / v % to about 5 w / v %. (Item 15) The aqueous suspension according to any one of the preceding items, wherein the concentration of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, in the aqueous suspension is about 0.3 w / v % to about 1 w / v %. (Item 16) An aqueous suspension comprising heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a non-ionic surfactant, wherein the heat treatment comprises heat treatment at a temperature lower than about 180°C, and the heat treatment is carried out for about 30 minutes to about 5 hours, the concentration of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, in the aqueous suspension is about 0.01 w / v % to about 5 w / v %, and the concentration of the non-ionic surfactant in the aqueous suspension is about 0.01 w / v % to about 0.05 w / v %. (Item 17) The aqueous suspension according to any one of the preceding items, wherein the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide.(Item 18) The aqueous suspension according to any one of the preceding items, comprising heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, wherein the suspended particles of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension are redispersed after shaking less than about 35 times when evaluated by shaking. (Item 19) The aqueous suspension according to any one of the preceding items, comprising heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, wherein the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension redisperses suspended particles after less than about 50 inversions when evaluated by an inversion procedure. (Item 20) An aqueous suspension comprising heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, wherein the aqueous suspension has improved redispersibility of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof. (Item 21) The aqueous suspension of any one of the preceding items, wherein the improved redispersibility is measured by shaking the suspension so that the suspended particles redisperse after shaking for less than about 35 times. (Item 22) The aqueous suspension according to any one of the preceding items, wherein the improved redispersibility is such that the suspended particles redisperse after less than about 50 inversions when assessed by inversion.(Item 23) An aqueous suspension comprising heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, wherein the average particle size (D50) of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is from about 1 μm to about 10 μm. (Item 24) A method for producing an aqueous suspension, comprising the steps of: heat-treating (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof; and mixing the heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a solvent. (Item 25) Heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof. (Item 26) The aqueous suspension according to any one of the preceding items, wherein the pH of the aqueous suspension is about 4 to about 8. (Item 27) The aqueous suspension according to any one of the preceding items, wherein the aqueous suspension is housed in a plastic container. (Item 28) The aqueous suspension according to any one of the preceding items, wherein the plastic container is made of polyethylene or polypropylene. (Item B1) An aqueous suspension comprising gamma-ray sterilized (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof. (Item B2) The aqueous suspension according to any one of the preceding items, further comprising a nonionic surfactant.(Item B3) An aqueous suspension comprising gamma-ray sterilized (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a non-ionic surfactant. (Item B4) The aqueous suspension according to any one of the above items, wherein the gamma-ray sterilization comprises gamma-ray treatment at about 10 to about 50 kGy. (Item B5) The aqueous suspension according to any one of the above items, wherein the gamma-ray sterilization comprises gamma-ray treatment at about 25 kGy. (Item B6) The aqueous suspension according to any one of the above items, wherein the concentration of the non-ionic surfactant in the aqueous suspension is about 0.0001 w / v % to about 0.1 w / v %. (Item B7) The aqueous suspension according to any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is about 0.001 w / v% to about 0.5 w / v%. (Item B8) The aqueous suspension according to any one of the preceding items, wherein the concentration of the nonionic surfactant in the aqueous suspension is about 0.01 w / v% to about 0.05 w / v%. (Item B9) The aqueous suspension according to any one of the preceding items, wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil. (Item B10) The aqueous suspension according to any one of the preceding items, wherein the nonionic surfactant is tyloxapol. (Item B11) The aqueous suspension according to any one of the preceding items, wherein the concentration of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.01 w / v % to about 5 w / v %.(Item B12) The aqueous suspension according to any one of the preceding items, wherein the concentration of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.3 w / v % to about 1 w / v %. (Item B13) An aqueous suspension comprising gamma-ray sterilized (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a non-ionic surfactant, wherein the gamma-ray sterilization comprises gamma-ray treatment at about 10 to about 50 kGy, the concentration of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, in the aqueous suspension is about 0.01 w / v % to about 5 w / v %, and the concentration of the non-ionic surfactant in the aqueous suspension is about 0.01 w / v % to about 0.05 w / v %. (Item B14) The aqueous suspension according to any one of the preceding items, wherein the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide.(Item B15) The aqueous suspension according to any one of the preceding items, which comprises gamma-ray sterilized (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, wherein the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension redisperses after shaking less than about 35 times when evaluated by shaking. (Item B16) The aqueous suspension according to any one of the preceding items, which comprises gamma-ray sterilized (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, wherein the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension redisperses after less than about 50 inversions when evaluated by an inversion procedure. (Item B17) An aqueous suspension comprising gamma-ray sterilized (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, wherein the aqueous suspension has improved redispersibility of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof. (Item B18) The aqueous suspension according to any one of the preceding items, wherein the improved redispersibility is such that, when evaluated by shaking, the suspended particles redisperse after about 35 or fewer shakes.(Item B19) The aqueous suspension according to any one of the preceding items, wherein the improved redispersibility is such that, when evaluated by inversion, the suspended particles redisperse after about 50 or fewer inversions. (Item B20) Gamma-ray sterilized (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof. (Item B21) The aqueous suspension according to any one of the preceding items, wherein the pH of the aqueous suspension is about 4 to about 8. (Item B22) The aqueous suspension according to any one of the preceding items, wherein the aqueous suspension is contained in a plastic container. (Item B23) The aqueous suspension according to any one of the preceding items, wherein the plastic container is made of polyethylene or polypropylene. (Item A1) A method for producing an aqueous suspension, comprising the steps of heat-treating (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, and mixing the heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a solvent. (Item A1-1) The method according to any one of the above items, wherein the heat treatment is a dry heat treatment. (Item A2) The method according to any one of the above items, wherein the heat treatment is a treatment within a sterilization step. (Item A2-2) The method according to any one of the above items, wherein the treatment within the sterilization step is a dry heat sterilization treatment. (Item A3) The method according to any one of the above items, further comprising a step of mixing a nonionic surfactant. (Item A4) The method according to any one of the above items, wherein the heat treatment comprises heat treatment at a temperature lower than about 180°C. (Item A5) The method according to any one of the above items, wherein the heat treatment comprises heat treatment at about 100 to about 175°C. (Item A6) The method according to any one of the above items, wherein the heat treatment comprises heat treatment at about 100 to about 170°C.(Item A7) The method according to any one of the above items, wherein the heat treatment comprises heat treatment at about 150 to about 170°C. (Item A8) The method according to any one of the above items, wherein the heat treatment is carried out for about 30 minutes to about 5 hours. (Item A9) The method according to any one of the above items, wherein the concentration of the nonionic surfactant in the aqueous suspension is about 0.0001 w / v% to about 1 w / v%. (Item A10) The method according to any one of the above items, wherein the concentration of the nonionic surfactant in the aqueous suspension is about 0.001 w / v% to about 0.5 w / v%. (Item A11) The method according to any one of the above items, wherein the concentration of the nonionic surfactant in the aqueous suspension is about 0.01 w / v% to about 0.05 w / v%. (Item A12) The method according to any one of the above items, wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil. (Item A13) The method according to any one of the above items, wherein the nonionic surfactant is tyloxapol. (Item A14) The method according to any one of the above items, wherein the concentration of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.01 w / v % to about 5 w / v %. (Item A15) The method according to any one of the preceding items, wherein the concentration of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.3 w / v % to about 1 w / v %.(Item A16) The method according to any one of the preceding items, wherein the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide. (Item A17) The method according to any one of the preceding items, wherein the pH of the aqueous suspension is about 4 to about 8. (Item A18) The method according to any one of the preceding items, wherein the heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, in the aqueous suspension redisperses suspended particles after shaking less than about 35 times when evaluated by shaking. (Item A19) The method according to any one of the preceding items, wherein the heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, in the aqueous suspension redisperses suspended particles after shaking less than about 50 times when evaluated by inversion. (Item A20) The method according to any one of the preceding items, wherein the redispersibility of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is improved. (Item A21) The method according to any one of the preceding items, wherein the improved redispersibility, when evaluated by shaking, means that the suspended particles are redispersed after shaking about 35 times or less. (Item A22) The method according to any one of the preceding items, wherein the improved redispersibility, when evaluated by inversion, means that the suspended particles are redispersed after inversion about 50 times or less.(Item A23) The method according to any one of the above items, wherein the average particle size of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 1 μm to about 10 μm. (Item A24) The method according to any one of the above items, wherein the aqueous suspension is contained in a plastic container. (Item A25) The method according to any one of the above items, wherein the plastic container is made of polyethylene or polypropylene. (Item C1) A method for producing an aqueous suspension, comprising the steps of: gamma-ray treating (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof; and mixing the gamma-ray-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a solvent.

[0008] According to the present disclosure, an aqueous suspension having excellent redispersibility can be provided.

[0009] By providing the above-mentioned features, the present disclosure can suppress the phenomenon of non-uniform dispersion of suspended particles, enable stable administration of the required amount of active ingredient, and realize stable and sufficient exertion of pharmacological effects, thereby contributing to improved patient adherence and convenience.

[0010] The present disclosure will be described below. Throughout this specification, singular expressions should be understood to include the plural concept unless otherwise specified. Therefore, singular articles (e.g., "a," "an," "the," etc. in English) should be understood to include the plural concept unless otherwise specified. Furthermore, it should be understood that terms used in this specification are used in the sense commonly used in the relevant field unless otherwise specified. Therefore, unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. In case of conflict, the present specification (including definitions) will prevail.

[0011] (Definitions) In this specification, unless otherwise specified, the term "about" means ±10% of the following numerical value.

[0012] In this specification, "or" is used when "at least one or more" of the items listed in the sentence can be employed. The same applies to "or" and "alternative." In this specification, when it is specified that "within" "a range of two values," the range includes the two values ​​themselves.

[0013] As used herein, the term "aqueous suspension" is used in the same sense as the term is commonly used in this field, and refers to a liquid agent containing at least a portion of water, in which the ingredients to be mixed are suspended and solid particles are present in the liquid. Since (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof has extremely low solubility in water, in the aqueous suspension of the present disclosure, (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof is in the form of suspended particles, although some of the particles remain dissolved.

[0014] As used herein, "pharmaceutically acceptable salts" refers to relatively non-toxic, inorganic or organic acid addition salts, or inorganic or organic base addition salts of compounds of the present disclosure.

[0015] As used herein, the term "solvate" refers to a compound of the present disclosure or a pharmaceutically acceptable salt thereof interacting with any solvent to form a group, including, for example, solvates with organic solvents (e.g., solvates with alcohols (ethanol, etc.)), hydrates, etc. When a hydrate is formed, it may be coordinated with any number of water molecules. Examples of hydrates include monohydrates, dihydrates, etc.

[0016] As used herein, "redispersibility" refers to the ease with which particles (in the case of a suspension, also referred to as "suspended particles") that have settled in the solvent of a liquid containing the particles can be uniformly redispersed throughout the liquid after the liquid has been stored for a certain period of time. As used herein, "redispersibility" is evaluated by a test involving shaking or inversion.

[0017] As used herein, "shaking operation" refers to the action of holding a container filled with an "aqueous suspension" and shaking it up and down in the hand. The "shaking operation" involves shaking the container up and down in a 10-15 cm range, then shaking it up and back down until it returns to the original position, counting as one shaking operation, and shaking five times at a speed of 1.1 seconds per set. The redispersibility test using the "shaking operation" is performed on three samples per formulation, and the average number of sets required for redispersion for each sample is calculated, and this average number is used as the number of shaking operations.

[0018] In this specification, "inversion" refers to the action of holding a container filled with an "aqueous suspension" and turning it upside down in one hand. The redispersibility test by "inversion" is conducted on three specimens per formulation, and one inversion is defined as the operation of inverting the container 180° upside down at a rate of one second, and then inverting it again 180° to return it to the upright position.

[0019] In this specification, "improved redispersibility" means that particles that have settled in a liquid containing particles, such as a suspension, become easier to disperse again. In a comparison of any formulation, if the number of "shaking operations" or "inversion operations" described above is reduced, it can be said that redispersibility has been improved.

[0020] As used herein, the term "average particle size of suspended particles" refers to the median particle size (D) of particles of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof. 50 ) and is a value measured using a laser diffraction particle size distribution analyzer.

[0021] In this specification, the term "nonionic surfactant" is also referred to as a nonionic surfactant, and refers to a surfactant in which the hydrophilic group portion is nonionic. Whether a surfactant is nonionic or not can be easily determined by a person skilled in the art, and can be determined by confirming that a surfactant does not ionize (does not exhibit ionicity) when dissolved in water. Examples of nonionic surfactants include tyloxapol, polyoxyl stearates (polyethylene glycol monostearate, polyethylene glycol 40 monostearate (MYS-40), polyethylene glycol 400 monostearate, etc.), polyoxyethylene sorbitan fatty acid esters (polyoxyethylene sorbitan monooleate (polysorbate 80), polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan tristearate, etc.), and polyoxyethylene hydrogenated castor oils (polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60 (HCO-60), etc.).

[0022] As used herein, "heat treatment" refers to the application of heat to a target substance, molecule, aqueous suspension, or composition, and may be any treatment that substantially heats the target substance, molecule, aqueous suspension, or composition. Examples of "heat treatment" include dry heat treatment, moist heat treatment, and high-pressure steam treatment. The heat treatment temperature may refer to the temperature of the target substance, molecule, aqueous suspension, or composition, or may be the temperature set in the device used for applying heat or the temperature displayed on a display. The heat treatment time may refer to the time during which the target substance, molecule, aqueous suspension, or composition is maintained at a predetermined temperature as an average temperature after the predetermined temperature is reached, or may be the time set in the device used for applying heat or the time displayed on a display. In the present disclosure, heat treatment (e.g., dry heat treatment, moist heat treatment, high-pressure steam treatment) refers to treatment of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, itself. The dry heat treatment can be applied to a powder of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof. The term "powder" refers to a granular material (composed of solid particles having a given particle size distribution, with interactions such as electrostatic forces and van der Waals forces acting between the individual particles).

[0023] As used herein, "sterilization" or "sterilization treatment" refers to the substantial removal, sterilization, or inactivation of viruses, microorganisms, etc. present in a target substance, molecule, aqueous suspension, or composition. Examples of sterilization include gamma ray sterilization, dry heat sterilization, and autoclave sterilization. Therefore, "gamma ray sterilization" refers to the sterilization of a target substance, molecule, aqueous suspension, or composition by irradiating the substance or molecule with gamma rays. Furthermore, "dry heat sterilization" refers to a treatment of sterilization by heating in a dry state. In the present disclosure, sterilization or sterilization treatment refers to treatment of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, itself. The gamma sterilization treatment may be applied to a powder of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof.

[0024] In this specification, the term "solvent" is used to encompass water, organic solvents, and mixtures of water and organic solvents, and may be sterilized by filtration or other sterilization treatments, and these sterilized solvents are also encompassed by the term "solvent" in this specification. In addition to water, organic solvents, or mixtures of water and organic solvents, solvents may contain any additives dissolved therein, such as thickeners, stabilizers, pH adjusters, buffers, and preservatives (antiseptics), and these additive-containing solvents are also encompassed by the term "solvent" in this specification.

[0025] (Preferred Embodiments) Preferred embodiments of the present disclosure will be described below. The embodiments provided below are provided for a better understanding of the present disclosure, and the scope of the present disclosure should not be limited to the following description. Therefore, it is clear that those skilled in the art can make appropriate modifications within the scope of the present disclosure in light of the description herein. In addition, the following embodiments of the present disclosure can be used alone or in combination.

[0026] (Aqueous Suspension) In one aspect of the present disclosure, there may be provided an aqueous suspension comprising heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof.

[0027] In another aspect of the present disclosure, there can be provided an aqueous suspension comprising heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a non-ionic surfactant.

[0028] In one aspect of the present disclosure, there can be provided an aqueous suspension comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, that has been heat-treated at about 150°C to about 170°C.

[0029] In another aspect of the present disclosure, there can be provided an aqueous suspension comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide heat-treated at about 150°C to about 170°C, or a pharmaceutically acceptable salt or solvate thereof, and a non-ionic surfactant.

[0030] In one aspect of the present disclosure, there can be provided an aqueous suspension comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, which has been sterilized by heat treatment at about 100°C to about 170°C.

[0031] In another aspect of the present disclosure, there may be provided an aqueous suspension comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, which has been sterilized by heat treatment at about 100°C to about 170°C, and a non-ionic surfactant.

[0032] In one aspect of the present disclosure, there can be provided an aqueous suspension comprising gamma-ray sterilized (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof.

[0033] In another aspect of the present disclosure, there may be provided an aqueous suspension comprising gamma-ray sterilized (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a non-ionic surfactant.

[0034] In one aspect of the present disclosure, there can be provided a method for producing an aqueous suspension, the method comprising the steps of heat-treating (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, and mixing the heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a solvent.

[0035] In another aspect of the present disclosure, there may be provided a method for producing an aqueous suspension, the method comprising the steps of gamma-ray sterilizing (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, and mixing the gamma-ray sterilized (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a solvent.

[0036] In one aspect of the present disclosure, there can be provided heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof.

[0037] In one aspect of the present disclosure, there can be provided (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, that has been heat-treated at about 150° C. to about 170° C.

[0038] In one aspect of the present disclosure, there is provided (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, which has been sterilized by heat treatment at about 100° C. to about 170° C.

[0039] In another aspect of the present disclosure, there may be provided gamma-sterilized (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof.

[0040] (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide includes the R-form (CAS No. 920332-28-1), the S-form (CAS No. 920332-29-2), or the racemic form (CAS No. 920332-27-0), and more preferably the R-form ((E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (also referred to as compound (1) in the present disclosure).

[0041] The pharmaceutically acceptable salt of the compound of the present disclosure is not particularly limited as long as it is a pharmaceutically acceptable salt, and specific examples thereof include mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; aliphatic monocarboxylic acids such as formic acid, acetic acid, propionic acid, butyric acid, valeric acid, enanthic acid, capric acid, myristic acid, palmitic acid, stearic acid, lactic acid, sorbic acid, and mandelic acid; aromatic monocarboxylic acids such as benzoic acid and salicylic acid; aliphatic dicarboxylic acids such as oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, malic acid, and tartaric acid; and citric acid. and organic sulfonic acids such as aliphatic sulfonic acids, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, etc., and aromatic sulfonic acids, such as benzenesulfonic acid, p-toluenesulfonic acid, etc.; inorganic base addition salts with metals such as alkali metals or alkaline earth metals, such as sodium, potassium, magnesium, calcium, etc.; and organic base addition salts with methylamine, ethylamine, ethanolamine, pyridine, lysine, arginine, ornithine, etc.

[0042] These salts can be obtained by a conventional method, for example, by mixing a solution containing an equivalent amount of a compound of the present disclosure and the desired acid or base, and collecting the desired salt by filtration or by distilling off the solvent. In addition, the compound of the present disclosure or a salt thereof can form a solvate with a solvent such as water or ethanol.

[0043] (E)-2-(7-Trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide has excellent Transient Receptor Potential Vanilloid 1 (hereinafter referred to as "TRPV1." TRPV1 is also called "Transient Receptor Potential Vanilloid 1" or "Vanilloid Receptor 1 (VR1)") antagonistic activity.

[0044] The R-form (compound (1)), S-form, or racemic form of ((E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide is described in WO 2007 / 010383, JP 4754566, JP 6230743, WO 2018 / 221543, JP 6830569, WO 2021 / 038889, and WO 2021 / 039023. The R-form (compound (1)), S-form, or racemic form can be produced by the production method described in the publication. The contents of the publication are incorporated herein by reference in their entirety.

[0045] TRPV1 was cloned from the dorsal root ganglion (DRG) as a capsaicin-responsive cation channel. It is also sensitive to heat above 43°C and protons, and is a TRP channel that has been studied as a key molecule in nociception (Biochemistry, Vol. 85, No. 7: 561-565). TRPV1 activity is known to increase during inflammation and tissue injury, inducing hyperalgesia. Therefore, TRPV1 has attracted attention as a potential drug target for pain treatment.

[0046] TRPV1 antagonists have been reported to be effective against various pain models, such as inflammatory pain, neuropathic pain, and osteoarthritis pain (Biochemistry, Vol. 85, No. 7: 561-565).

[0047] In one embodiment of the present disclosure, (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, is heat-treated, and the heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof is mixed with a solvent to form an aqueous suspension, thereby improving the redispersibility of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof.

[0048] In another embodiment of the present disclosure, (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, is subjected to gamma ray sterilization, and the gamma ray sterilized (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof is mixed with a solvent to form an aqueous suspension, thereby improving the redispersibility of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof.

[0049] In one embodiment of the present disclosure, (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, can be present in the aqueous suspension of the present disclosure at a concentration of generally about 0.01 w / v % to about 5 w / v %, preferably about 0.1 w / v % to about 3 w / v %, more preferably about 0.2 w / v % to about 2 w / v %, particularly preferably about 0.2 w / v % to about 1.5 w / v %, and even more preferably about 0.3 w / v % to about 1.0 w / v %.

[0050] In one embodiment of the present disclosure, when the R-isomer of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, is used, it can be present in the aqueous suspension of the present disclosure at a concentration of generally about 0.01 w / v % to about 5 w / v %, preferably about 0.1 w / v % to about 3 w / v %, more preferably about 0.2 w / v % to about 2 w / v %, particularly preferably about 0.2 w / v % to about 1.5 w / v %, and even more preferably about 0.3 w / v % to about 1.0 w / v %.

[0051] In one embodiment of the present disclosure, the heat treatment of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, can be carried out as a treatment within a sterilization process of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof. The heat treatment temperature can usually be lower than about 180°C, preferably about 175°C or lower, more preferably about 100 to about 175°C, particularly preferably about 100 to about 170°C, even more preferably about 120 to about 170°C, still more preferably about 145 to about 175°C, and most preferably about 150 to about 170°C.

[0052] In one embodiment of the present disclosure, the heat treatment time for (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, is usually from about 10 minutes to about 24 hours, more preferably from about 30 minutes to about 12 hours, particularly preferably from about 30 minutes to about 8 hours, and even more preferably from about 30 minutes to about 5 hours.

[0053] In one embodiment of the present disclosure, gamma ray sterilization of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, can be performed as a treatment within the sterilization process of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, and the dose of the gamma ray sterilization can be typically about 10 to about 50 kGy, more preferably about 25 kGy.

[0054] In one embodiment of the present disclosure, the nonionic surfactant is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include tyloxapol, polyoxyl stearates (polyethylene glycol monostearate, polyethylene glycol 40 monostearate (MYS-40), polyethylene glycol 400 monostearate, etc.), polyoxyethylene sorbitan fatty acid esters (polyoxyethylene sorbitan monooleate (polysorbate 80), polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan tristearate, etc.), and polyoxyethylene hydrogenated castor oils (polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60 (HCO-60), etc.). These nonionic surfactants may be used alone or in combination of two or more. From the viewpoint of redispersibility or stability of the aqueous suspension, the nonionic surfactant is preferably tyloxapol, polysorbate, polyethylene glycol monostearate, or polyoxyethylene hydrogenated castor oil, more preferably tyloxapol, polysorbate, or polyethylene glycol monostearate, and even more preferably tyloxapol.

[0055] In one embodiment of the present disclosure, the nonionic surfactant can be present in the aqueous suspension of the present disclosure at a concentration of about 0.0001 w / v % to about 1 w / v %, preferably about 0.0005 w / v % to about 0.5 w / v %, more preferably about 0.001 w / v % to about 0.5 w / v %, particularly preferably about 0.005 w / v % to about 0.1 w / v %, and even more preferably about 0.01 w / v % to about 0.05 w / v %.

[0056] (Redispersibility) (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, has low solubility in water. Therefore, in the absence of a dispersant such as a nonionic surfactant, an ionic surfactant, or a water-soluble polymer, the particles float on the water surface, making it impossible to prepare an aqueous suspension. In addition, when a dispersant other than a nonionic surfactant is used, the dispersant must be incorporated at a concentration substantially exceeding the pharmaceutically acceptable concentration, making it essential to incorporate a nonionic surfactant into the aqueous suspension. According to the present disclosure, an aqueous suspension having improved redispersibility can be provided by subjecting (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, to heat treatment in the presence of a nonionic surfactant as a dispersant.

[0057] In another aspect of the present disclosure, an aqueous suspension having improved redispersibility can be provided by subjecting (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, to gamma ray sterilization.

[0058] In one embodiment, the redispersibility can be determined to be improved when the number of shakings required for the redispersion is generally less than about 35 times, preferably about 30 times or less, more preferably about 25 times or less, and particularly preferably about 20 times or less.

[0059] Measurements using the falling operation can be said to reproduce the evaluation when used by patients whose hands have weakened due to some kind of disability or symptom, making it difficult to redisperse the tablet by shaking, and therefore can also be said to evaluate the redispersibility when used by these patients and elderly people.

[0060] In one embodiment, the redispersibility can be determined to be improved when the number of inversion operations required for the redispersion is generally less than about 50 times, preferably about 45 times or less.

[0061] In one embodiment, the redispersibility can be evaluated by any means, for example, by filling a container with the aqueous suspension of the present disclosure and measuring the number of times the container is shaken at any speed and / or any amplitude, or inverted, until the suspended particles are redispersed.

[0062] In one embodiment, the average particle size (D) of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof in an aqueous suspension of the present disclosure is 50 ) is not particularly limited, but can be generally about 1 μm to about 10 μm, preferably about 0.5 μm to about 5 μm, particularly preferably about 2 μm to about 4 μm, further preferably about 2.3 μm to about 3.3 μm, and most preferably about 2.1 μm to about 3.3 μm. By setting the average particle size in this range, redispersibility can be improved.

[0063] In one embodiment, the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension of the present disclosure can be used in a crystalline form, and the crystalline form is not particularly limited as long as it does not affect redispersibility. For example, in the present disclosure, Type I crystals, Type II crystals, Type III crystals, or mixtures thereof of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide disclosed in WO 2018 / 221543, Japanese Patent No. 6230743, etc. can be used. Preferably, Type I crystals are used.

[0064] In one embodiment of the present disclosure, the aqueous suspension is an ophthalmic suspension, and may be provided as an ophthalmic injection, eye drop, or ophthalmic irrigation solution. For example, the ophthalmic suspension may be provided in the form of a suspension in which the active ingredient is suspended in an aqueous solvent (e.g., phosphate buffered saline), or in the form of a solution in which the active ingredient is dissolved.

[0065] In one embodiment of the present disclosure, the aqueous suspension may be an eye drop for treating dry eye. Dry eye is a disease accompanied by subjective symptoms such as ocular discomfort, and requires long-term and regular treatment. In addition, since dry eye treatments are generally administered frequently, there is a strong demand for formulations that are easy to use and that facilitate patient adherence. Furthermore, in the case of a suspension with poor redispersibility, there is a concern that the suspended particles may not be uniformly dispersed, the desired active ingredient may not be administered, and the pharmacological effect may not be fully exerted. From these perspectives, redispersibility is a major issue in eye drops for treating dry eye, and the provision of an aqueous suspension with excellent redispersibility according to the present disclosure is of great value.

[0066] The aqueous suspensions of the present disclosure may be administered by any suitable route as determined by one of skill in the art, and may be formulated to be suitable for administration by a route selected from, but not limited to, ocular injection, topical application (including application to the eye), eye drops, intravenous injection, infusion, oral, parenteral, transdermal, and the like.

[0067] Additives and / or Excipients Aqueous suspensions of the present disclosure may contain any pharmaceutically acceptable additives and / or excipients known in the art, including, but not limited to, viscosity agents, stabilizers, pH adjusting agents, buffers, and preservatives.

[0068] The thickener is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include water-soluble polymers such as carboxyvinyl polymer, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, xanthan gum, sodium chondroitin sulfate, sodium hyaluronate, etc.; cellulose-based polymers such as hydroxyethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, etc. These thickeners may be used alone or in combination of two or more.From the viewpoint of redispersibility, cellulose-based polymers are preferred, and methyl cellulose is particularly preferred.

[0069] The stabilizer is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include polyvinylpyrrolidone, monoethanolamine, cyclodextrin, dextran, ascorbic acid, tocopherol, dibutylhydroxytoluene, sulfites, sodium edetate, etc., and the content thereof is preferably about 0.001 w / v % to about 1 w / v % based on the total amount of the aqueous suspension.

[0070] The pH adjuster is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include acids such as hydrochloric acid, acetic acid, boric acid, aminoethylsulfonic acid, and epsilon-aminocaproic acid; alkalis such as sodium hydroxide, potassium hydroxide, borax, triethanolamine, monoethanolamine, sodium bicarbonate, and sodium carbonate; and the content thereof is, for example, 0 to about 20 w / v % based on the total amount of the aqueous suspension.

[0071] In one embodiment of the present disclosure, the aqueous suspension of the present disclosure can be mixed with the above-mentioned pH adjuster as needed to adjust the pH to generally about 4 to about 8, preferably about 5.0 to about 8.0, more preferably about 6.0 to about 8.0, particularly preferably about 7.0 to about 8.0, and even more preferably about 7.2 to about 7.8.

[0072] The buffer used in the aqueous suspension of the present disclosure is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include borate buffer, phosphate buffer, Tris buffer, citrate buffer, tartrate buffer, acetate buffer, amino acid buffer, etc., but from the viewpoint of redispersibility or stability of the aqueous suspension, borate buffer or phosphate buffer is preferred, and borate buffer is particularly preferred.

[0073] The concentration of the buffering agent may be appropriately set within a range that can impart the desired buffering ability to the aqueous liquid preparation, and may be, for example, about 0.1 w / v % to about 10 w / v %, and from the viewpoint of improving redispersibility or stability, preferably about 1 w / v % to about 5 w / v %, more preferably about 1 w / v % to about 3 w / v %.

[0074] The boric acid buffer is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include boric acid and / or its salts. The boric acid is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include orthoboric acid, metaboric acid, tetraboric acid, etc. The salt of boric acid is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include metal salts such as sodium salt, potassium salt, calcium salt, magnesium salt, and aluminum salt; and organic amine salts such as triethylamine, triethanolamine, morpholine, piperazine, and pyrrolidine. Boric acid or its salts may be used alone or in combination of two or more. Furthermore, a preferred embodiment of the boric acid buffer is a combination of boric acid and borax.

[0075] When boric acid and borax are used in combination, the ratio of boric acid to borax is not particularly limited, but may be, for example, 10 to 300 parts by mass, preferably 10 to 250 parts by mass, more preferably 30 to 100 parts by mass, and particularly preferably 40 to 60 parts by mass of borax per 100 parts by mass of boric acid.

[0076] Specific examples of phosphate buffers include phosphoric acid and / or its salts. Phosphate salts are not particularly limited as long as they are pharmaceutically acceptable, and include, for example, dialkali metal hydrogen phosphates such as disodium hydrogen phosphate and dipotassium hydrogen phosphate; alkali metal dihydrogen phosphates such as sodium dihydrogen phosphate and potassium dihydrogen phosphate; and trialkali metal phosphates such as trisodium phosphate and tripotassium phosphate. Phosphate salts may also be in the form of solvates such as hydrates, for example, disodium hydrogen phosphate may be in the form of a dodecahydrate, and sodium dihydrogen phosphate may be in the form of a dihydrate. Phosphate buffers may be selected from phosphoric acid and its salts and used alone or in combination of two or more. Among phosphoric acid and its salts, preferred are phosphates, more preferably at least one of dialkali metal hydrogen phosphates and alkali metal dihydrogen phosphates, and particularly preferably at least one of disodium hydrogen phosphate and sodium dihydrogen phosphate.

[0077] Examples of Tris buffers include Tris (also known as trishydroxymethylaminomethane) and / or its salts. The Tris salts are not particularly limited as long as they are pharmaceutically acceptable, and examples include acetate, hydrochloride, maleate, sulfonate, and the like. As the Tris acid buffer, one selected from Tris and its salts may be used alone, or two or more may be used in combination. In another embodiment, specific examples of Tris buffers include trometamol and / or its salts. As the salt of trometamol, there are no particular limitations, as long as it is pharmaceutically acceptable, and examples include organic acid salts such as acetate; and inorganic acid salts such as hydrochloride and sulfonate. As the Tris acid buffer, one selected from trometamol and its salts may be used alone, or two or more may be used in combination. Among trometamol and its salts, trometamol is preferred.

[0078] Specific examples of citrate buffers include citric acid and / or its salts. The citric acid salts are not particularly limited as long as they are pharmaceutically acceptable, and include, for example, alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt. The citric acid salt may also be in the form of a solvate such as a hydrate. As the citrate buffer, one selected from citric acid and its salts may be used alone, or two or more may be used in combination. Among citric acid and its salts, preferred are citric acid salts, more preferred are alkali metal citric acid salts, and particularly preferred is sodium citrate.

[0079] Specific examples of tartaric acid buffers include tartaric acid and / or its salts. The salts of tartaric acid are not particularly limited as long as they are pharmaceutically acceptable, and include, for example, alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts. The salts of tartaric acid may also be in the form of solvates such as hydrates. As the tartaric acid buffer, one selected from tartaric acid and its salts may be used alone, or two or more may be used in combination.

[0080] Specific examples of acetate buffers include acetic acid and / or its salts. The salts of acetic acid are not particularly limited as long as they are pharmaceutically acceptable, and examples include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; and ammonium salts. Furthermore, the salts of acetic acid may be in the form of a solvate such as a hydrate. Acetic acid and its salts may be used singly or in combination as the acetate buffer.

[0081] Specific examples of the amino acid buffer include acidic amino acids and / or their salts. Specific examples of the acidic amino acids include aspartic acid and glutamic acid. The salts of acidic amino acids are not particularly limited as long as they are pharmaceutically acceptable, and examples include alkali metal salts such as sodium salts and potassium salts. As the amino acid buffer, one kind selected from acidic amino acids and their salts may be used alone, or two or more kinds may be used in combination.

[0082] The preservative is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include sorbic acid, potassium sorbate, parahydroxybenzoic acid esters such as methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, and butyl parahydroxybenzoate, chlorhexidine gluconate, quaternary ammonium salts such as benzalkonium chloride, benzethonium chloride, and cetylpyridinium chloride, alkylpolyaminoethylglycine, chlorobutanol, polyquad, polyhexamethylene biguanide, and chlorhexidine. The content thereof can be appropriately varied depending on the type, and can be, for example, about 0.0001 w / v % to about 0.2 w / v % based on the total amount of the aqueous suspension.

[0083] When preparing eye drops, for example, the desired components described above can be dissolved or suspended in an aqueous solvent such as sterilized purified water, physiological saline, or a buffer solution (e.g., phosphate buffer, citrate buffer, or acetate buffer), or in a non-aqueous solvent such as a vegetable oil such as cottonseed oil, soybean oil, sesame oil, or peanut oil, and the like, and the resulting solution is adjusted to a predetermined osmotic pressure and subjected to a sterilization treatment such as filtration sterilization.

[0084] (Container) The container for housing the aqueous suspension of the present disclosure is not particularly limited, and examples thereof include glass containers and plastic containers. Plastic containers can be made of any material, such as polyester (polyethylene terephthalate, polyarylate), polycarbonate, polyethylene, polypropylene, mixtures thereof, or mixtures of these with other materials. Containers used in the present disclosure may be those used in the medical field or other fields. In one embodiment, the container can be made of any material that meets the "Standards for Plastic Containers for Ophthalmic Solutions" in Japan or other equivalent standards.

[0085] The shape of the container to be used may be any shape, and generally any shape suitable for eye drops can be used.

[0086] In certain embodiments, the aqueous suspension of the present disclosure can be filled into any eye drop container commonly used in the medical field, for example, a polyethylene (preferably low-density polyethylene) or polypropylene, preferably a colorless polypropylene container.

[0087] (General Techniques) The molecular biological, biochemical and microbiological techniques used herein are well known and commonly used in the art, and are described in, for example, Sambrook J. et al. (1989). Molecular Cloning: A Laboratory Manual, Cold Spring Harbor and its 3rd Ed. (2001); Ausubel, F. M. (1987). Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Ausubel, F. M. (1989). Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Innis, M. A. (1990). PCR Protocols: A Guide to Methods and Applications, Academic Press; Ausubel, F. M. (1992). Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates; Ausubel, FM (1995). Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates; Innis, MA et al. (1995). PCR Strategies, Academic Press; Ausubel, FM (1999).Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Wiley, and annual updates; Sninsky, JJet al.(1999).PCR Applications: Protocols for Functional Genomics, Academic Press, Gait, MJ(1985).Oligonucleotide Synthesis: A Practical Approach, IRL Press; Gait, MJ(1990).Oligonucleotide Synthesis: A Practical Approach, IRL Press; Eckstein, F. (1991).Oligonucleotides and Analogues: A Practical Approach, IRL Press; Adams, RL et al.(1992).The Biochemistry of the Nucleic Acids, Chapman & Hall; Shabarova, Z. et al.(1994).Advanced Organic Chemistry of Nucleic Acids, Weinheim; Blackburn, GM et al.(1996).Nucleic Acids in Chemistry and Biology, Oxford University Press; Hermanson, GT (1996). Bioconjugate Techniques, Academic Press; Special Edition of Experimental Medicine "Gene Transfer & Expression Analysis Experimental Methods," Yodosha, 1997. These are incorporated herein by reference in their entirety (perhaps in their entirety).

[0088] All references cited herein, including scientific literature, patents, patent applications, and the like, are incorporated by reference in their entirety to the same extent as if each were specifically set forth.

[0089] The present disclosure has been described above by showing preferred embodiments for ease of understanding. Hereinafter, the present disclosure will be described based on examples. However, the above description and the following examples are provided for illustrative purposes only and are not intended to limit the present disclosure. Therefore, the scope of the present disclosure is not limited to the embodiments or examples specifically described herein, but is limited only by the scope of the claims.

[0090] (Test Example 1: Change in redispersibility depending on heat treatment temperature of drug substance) Preparation of suspension A base solution was prepared according to the composition shown in Tables 1 and 2, and compound (1) was added thereto and stirred and dispersed to obtain a suspension. Tyloxapol manufactured by AMRI Rensselaer (Curia Global, Inc.) was used. The above-mentioned type I crystal was used as compound (1).

[0091] The prepared suspension was stirred with a stirrer and 5 mL of each was dispensed into an eye dropper container. The eye dropper container used was a colorless polyethylene container (the same container used for GatiFlo ophthalmic solution 0.3% (manufactured and sold by Senju Pharmaceutical Co., Ltd.)).

[0092] Redispersibility Evaluation Evaluation method by inversion: Complete settling of suspended particles in the suspension filled in the eye drop container was confirmed. The inversion operation (the action of holding the container in the hand and turning it upside down) was repeated until the precipitate disappeared from the bottom and walls of the eye drop container and redispersion occurred. Note that one inversion was defined as an operation of turning the container upside down 180° at a rate of 1 second, then turning it 180° again to the upright position. The number of inversions required to redisperse the particles was counted. The test was conducted on three samples per formulation, and the average number of inversions was calculated.

[0093] Evaluation method by shaking: Complete settling of suspended particles in the suspension filled in the eye drop container was confirmed. Five shakings were counted as one set, and shaking was repeated until the precipitate disappeared from the bottom and walls of the eye drop container. Shaking was performed up and down over a width of 10 to 5 cm, with one shaking being defined as shaking from down to returning to the original position, at a speed of 1.1 seconds per set. The number of sets required until redispersion was counted, and the number of shakings was calculated.

[0094] Measurement of particle size After shaking the sample until the precipitate was redispersed, approximately 1 mL of the sample was dropped into the dispersion tank of a laser diffraction particle size distribution analyzer (SALD-2300). After ultrasonic treatment for 2 minutes, the particle size distribution was measured, and the values ​​of D10, D50, and D90 were taken as the particle size.

[0095] Results The results are shown in Tables 1 and 2. The aqueous suspension in which the compound (1) heat-treated at 150 to 170° C. was dispersed showed good redispersibility.

[0096]

[0097]

[0098] Test Example 2: Heat Treatment Time Preparation of Suspension A base solution was prepared according to the composition shown in Table 3, and Compound (1) was added thereto and dispersed by stirring to obtain a suspension.

[0099] Placement in a container was carried out in the same manner as in Test Example 1.

[0100] Evaluation of redispersibility: The redispersibility was evaluated in the same manner as in Test Example 1.

[0101] Results The results are shown in Table 3. When the heat treatment time was 30 minutes to 5 hours, the aqueous suspension had good redispersibility.

[0102]

[0103] Test Example 3: Changes in redispersibility due to differences in surfactant Preparation of suspension A base solution was prepared according to the composition shown in Table 4, and compound (1) was added thereto and stirred to obtain a suspension. Tyloxapol manufactured by AMRI Rensselaer (Curia Global, Inc.), polysorbate 80 manufactured by NOF Corp., polyethylene glycol monostearate 40 (MYS-40) manufactured by Nippon Surfactant Industry Co., Ltd., and polyoxyethylene hydrogenated castor oil 60 manufactured by Nippon Surfactant Industry Co., Ltd. were used. The above-mentioned type I crystals were used as compound (1).

[0104] Placement in a container was carried out in the same manner as in Test Example 1.

[0105] Evaluation of redispersibility: The redispersibility was evaluated in the same manner as in Test Example 1.

[0106] Results The results are shown in Table 4. When any of the nonionic surfactants was used, the aqueous suspensions in which compound (1) heat-treated at 160°C was dispersed showed good redispersibility.

[0107]

[0108] Test Example 4: Surfactant concentration Preparation of suspension A base solution was prepared according to the composition shown in Table 5, and compound (1) was added thereto and stirred to obtain a suspension. Tyloxapol manufactured by AMRI Rensselaer (Curia Global, Inc.) was used. The above-mentioned type I crystal was used as compound (1).

[0109] Placement in a container was carried out in the same manner as in Test Example 1.

[0110] Evaluation of redispersibility: The redispersibility was evaluated in the same manner as in Test Example 1.

[0111] Results The results are shown in Table 5. When the tyloxapol concentration was in the range of 0.01% to 0.04%, the aqueous suspensions had good redispersibility.

[0112]

[0113] (Test Example 5: Changes in redispersibility due to differences in sterilization method) Preparation of suspension A base solution was prepared according to the composition shown in Table 6, and compound (1) was added thereto and stirred to obtain a suspension. Tyloxapol manufactured by AMRI Rensselaer (Curia Global, Inc.) was used. The above-mentioned type I crystal was used as compound (1). In Comparative Example 7, compound (1) irradiated with approximately 25 kGy of electron beam was used, and in Example 13, compound (1) irradiated with approximately 25 kGy of gamma ray was used. In Example 14, compound (1) sterilized by dry heat at 160°C for 2 hours was used.

[0114] Placement in a container was carried out in the same manner as in Test Example 1.

[0115] Evaluation of redispersibility: The redispersibility was evaluated in the same manner as in Test Example 1.

[0116] Results The results are shown in Table 6. The aqueous suspension in which the gamma-ray-treated compound (1) was dispersed showed good redispersibility.

[0117]

[0118] (Test Example: Stability of formulations using dry heat drug substance) Preparation of suspension A suspension was obtained according to the composition shown in Table 7. Tyloxapol manufactured by AMRI Rensselaer (Curia Global, Inc.) was used. The above-mentioned type I crystal was used as compound (1).

[0119]

[0120] Placement in a container was carried out in the same manner as in Test Example 1.

[0121] Storage Storage was carried out under the following conditions: Storage conditions: 60±2°C (average 60.1°C), humidity Storage period: Initial, 2 weeks, 4 weeks

[0122] pH Measurement pH was measured according to the pH measurement method of the Japanese Pharmacopoeia, i.e., using a pH meter with a glass electrode.

[0123] Measurement of Osmolality Osmolality was measured according to the Japanese Pharmacopoeia General Test Method, Osmolality Measurement Method (Osmolality Measurement Method).

[0124] Content measurement / impurity measurement In Example 15, a two-fold dilution with acetonitrile was used as the sample solution. In Example 16, 2 mL of this product was accurately measured, and mobile phase B was added to dissolve to make exactly 20 mL, which was used as the sample solution. Separately, approximately 20 mg of compound (1) was accurately measured, and mobile phase B was added to dissolve to make exactly 20 mL, which was used as standard solution A. 2 mL of this solution was accurately measured, and mobile phase B was added to make exactly 20 mL, which was used as standard solution B. Standard solution B was used in Example 15, and standard solution A in Example 16. 10 μL each of the sample solution and standard solution was accurately taken and tested by liquid chromatography under the following conditions.

[0125] Test conditions: Detector: UV spectrophotometer (measurement wavelength: 250 nm); Column: A commercially available column was used, consisting of a stainless steel tube with an inner diameter of 4.6 mm and a length of 250 mm, packed with 5 μm octadecylsilylated silica gel for liquid chromatography. Column temperature: A constant temperature of around 40°C. Mobile phase A: 1.79 g of disodium hydrogen phosphate dodecahydrate was added to 1000 mL of water and dissolved. Phosphoric acid was added to this solution to adjust the pH to 6.5. 350 mL of acetonitrile was added to 650 mL of this solution and mixed. Mobile phase B: Acetonitrile / water mixture (80:20). Mobile phase delivery: The mixing ratio of mobile phase A and mobile phase B was controlled using the linear concentration gradient shown in the table below.

[0126] Measurement of particle size: This was carried out in the same manner as in Test Example 1.

[0127] Results The results of n=3 experiments are shown in Table 8. All samples were found to be stable for 4 weeks.

[0128]

[0129] (Note) While the present disclosure has been illustrated using preferred embodiments thereof, it is understood that the scope of the present disclosure should be construed solely by the scope of the claims. It is understood that the patents, patent applications, and other documents cited herein are incorporated by reference into this specification in their entirety as if the contents themselves were specifically set forth herein. This application claims priority to Japanese Patent Application No. 2022-156060, filed on September 29, 2022, with the Japan Patent Office, and this application is incorporated by reference in its entirety.

[0130] The present disclosure is applicable to fields such as medicine, pharmaceuticals, healthcare, biology, and biochemistry.

Claims

1. An aqueous suspension comprising heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof.

2. The aqueous suspension according to claim 1, wherein the heat treatment is a treatment within a sterilization process.

3. An aqueous suspension according to any one of claims 1 or 2, further comprising a non-ionic surfactant.

4. An aqueous suspension according to any one of claims 1 to 3, wherein the heat treatment comprises heat treatment at a temperature below about 180°C.

5. An aqueous suspension according to any one of claims 1 to 4, wherein the heat treatment comprises heat treatment at about 100 to about 175°C.

6. An aqueous suspension according to any one of claims 1 to 5, wherein the heat treatment comprises heat treatment at about 150 to about 170°C.

7. An aqueous suspension according to any one of claims 1 to 6, wherein the heat treatment is carried out for about 30 minutes to about 5 hours.

8. An aqueous suspension according to any one of claims 3 to 7, wherein the concentration of the nonionic surfactant in the aqueous suspension is from about 0.0001 w / v % to about 1 w / v %.

9. The aqueous suspension according to any one of claims 3 to 8, wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil.

10. The aqueous suspension according to any one of claims 1 to 9, wherein the concentration of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, in the aqueous suspension is from about 0.01 w / v % to about 5 w / v %.

11. The aqueous suspension according to any one of claims 1 to 10, wherein the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide.

12. An aqueous suspension comprising heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, wherein the aqueous suspension has improved redispersibility of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof.

13. The aqueous suspension of claim 12, wherein the improved redispersibility is such that the suspended particles redisperse after less than about 35 shakings, as assessed by shaking.

14. The aqueous suspension of claim 12 or 13, wherein the improved redispersibility is such that the suspended particles redisperse after less than about 50 inversions, as assessed by inversion.

15. An aqueous suspension comprising heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, wherein the average particle size (D50) of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is from about 1 μm to about 10 μm.

16. A method for producing an aqueous suspension, comprising the steps of: heat-treating (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof; and mixing the heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a solvent.

17. Heat-treated (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof.